Method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -16434.15% · OPTIONAL
· Services-Misc Health & Allied Services, NEC
RESEARCH SNAPSHOTBioRestorative Therapies, Inc.'s latest supported as-filed period reports revenue of $23,170; gross margin moved 2024 basis points lower on the same comparison basis. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -16434.15% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value -7.32% · CORE
Level · gp.fundamentals.gross_margin
Raw value 68.13% · CORE
Level · gp.fundamentals.operating_margin
Raw value -14612.57% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 8313.82% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 1252.55% · OPTIONAL
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Shares outstanding changed +239.5% from the comparable as-filed period. The change ranks at the 100th percentile of 6 prior comparable changes.
Operating cash flow changed -37.0% from the comparable as-filed period.
Each point keeps the date investors could first observe it and its accession.
BRTX · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001213900-26-099018SEC ↗8-K/ASep 10, 2026Period Aug 26, 20260001213900-26-098820SEC ↗8-KSep 2, 2026Period Sep 2, 20260001213900-26-096810SEC ↗8-KSep 2, 2026Period Aug 26, 20260001213900-26-096337SEC ↗8-KAug 25, 2026Period Aug 21, 20260001213900-26-093566SEC ↗8-KAug 14, 2026Period Aug 7, 20260001493152-26-038391SEC ↗8-KJul 16, 2026Period Jul 8, 20260001493152-26-033593SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Oct 6, 2025Filed Oct 20, 2025 | ALSTODT LANCEPresident, CEO, COB | Grant Or AwardDirect | 11,719 | $0 | $0 | Form 4 ↗ |
| Oct 6, 2025Filed Oct 20, 2025 | Silva FranciscoVP of Research and Development | Grant Or AwardDirect | 11,719 | $0 | $0 | Form 4 ↗ |
| Oct 6, 2025Filed Oct 20, 2025 | Silva FranciscoVP of Research and Development | Grant Or AwardDirect | 11,719 | $2 | $18,750 | Form 4 ↗ |
| Oct 6, 2025Filed Oct 20, 2025 | ALSTODT LANCEPresident, CEO, COB | Grant Or AwardDirect | 15,625 | $2 | $25,000 | Form 4 ↗ |
| Feb 14, 2025Filed Feb 19, 2025 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Operating income changed +29.6% from the comparable as-filed period.
Operating margin changed +461756 basis points from the comparable as-filed period.
Gross margin changed -2024 basis points from the comparable as-filed period.
Cash & equivalents changed +153.3% from the comparable as-filed period.
Current assets changed -59.4% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-03-31. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001021771-26-000093| Kristal Robert EugeneChief Financial Officer |
| Grant Or AwardDirect |
| 166,492 |
| $0 |
| $0 |
| Form 4 ↗ |
| Feb 14, 2025Filed Feb 19, 2025 | ALSTODT LANCEPresident, CEO, COB | Grant Or AwardDirect | 791,885 | $0 | $0 | Form 4 ↗ |
| Feb 14, 2025Filed Feb 19, 2025 | Silva FranciscoVP of Research and Development | Grant Or AwardDirect | 768,979 | $0 | $0 | Form 4 ↗ |
| Feb 14, 2025Filed Feb 19, 2025 | Rosa David ADirector | Grant Or AwardDirect | 52,632 | $0 | $0 | Form 4 ↗ |
| Feb 14, 2025Filed Feb 19, 2025 | Williams Patrick F.Director | Grant Or AwardDirect | 52,632 | $0 | $0 | Form 4 ↗ |
| Feb 14, 2025Filed Feb 19, 2025 | Kukekov Nickolay V.Director | Grant Or AwardDirect | 52,632 | $0 | $0 | Form 4 ↗ |
| Oct 28, 2024Filed Nov 5, 2024 | Broadrick DaleReporting owner | Open Market SaleDirect | 1,112 | $2 | $1,757 | Form 4 ↗ |
| Apr 9, 2024Filed Apr 10, 2024 | Silva FranciscoVP of Research and Development | Open Market PurchaseDirect | 6,600 | $1 | $8,250 | Form 4 ↗ |
| Apr 8, 2024Filed Apr 10, 2024 | Silva FranciscoVP of Research and Development | Open Market PurchaseDirect | 476 | $1 | $538 | Form 4 ↗ |
| Apr 8, 2024Filed Apr 10, 2024 | Silva FranciscoVP of Research and Development | Open Market PurchaseDirect | 1,232 | $1 | $1,441 | Form 4 ↗ |
| Mar 18, 2024Filed Mar 20, 2024 | Silva FranciscoVP of Research and Development | Tax WithholdingDirect | 17,193 | $1 | $23,898 | Form 4 ↗ |
| Mar 18, 2024Filed Mar 20, 2024 | ALSTODT LANCEPresident, CEO, COB | Tax WithholdingDirect | 17,633 | $1 | $24,510 | Form 4 ↗ |